TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35863991
Drug: Non-Bevacizumab (non-BEV)
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Non-Bevacizumab (non-BEV) during second-line chemotherapy
Study: 33472921
Drug: IV tPA
Normalized name: tPA
DrugBank: Phorbol 12-myristate 13-acetate diester (DB17045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV tPA treatment
Study: 37697134
Drug: Sildenafil (PDE-5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (PDE-5 inhibitor)
Study: 35556322
Drug: Beetroot juice
Normalized name: tamarind juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beetroot juice (BRJ; 140 ml containing 800 mg nitrate per day)
Study: 35556322
Drug: Placebo (140
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (140 ml nitrate-depleted BRJ, daily)
Study: 32093630
Drug: Treatment 1
Normalized name: CVS Acne Treatment 10% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 1 (T1) - messages with information on their own adherence levels
Study: 32093630
Drug: Treatment 2
Normalized name: epoch Blemish Treatment 2 % Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment 2 (T2) - messages with information on their own adherence and peer adherence levels
Study: 35709207
Drug: Face-to-face (FTF)
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face (FTF) pain management education in seven weekly sessions
Study: 32139267
Drug: Eldecalcitol (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eldecalcitol (0.75 μg/day)
Study: 33396567
Drug: Long chain
Normalized name: long chain triglycerides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long chain omega-3 polyunsaturated fatty acids (LC n-3 PUFAs) at a dosage of 1.8 g/day for 12 weeks
Study: 36867173
Drug: Bupropion augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion augmentation
Study: 33117349
Drug: High throughput
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High throughput screening platform using one-bead-one-compound (OBOC) libraries for IgE epitope detection.
Study: 35995130
Drug: School-supervised asthma
Normalized name: schorl tourmaline
Approvals — FDA: no, EMA: no, PMDA: no
Description: School-supervised asthma therapy
Study: 34171959
Drug: Vericiguat (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vericiguat (target dose 10 mg once daily)
Study: 34999610
Drug: Ulinastatin (300,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ulinastatin (300,000 units mixed with 100 mL of normal saline)
Study: 34999610
Drug: Control (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (100 mL of normal saline)
Study: 33634589
Drug: liraglutide (0.6,
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide (0.6, 1.2, and 1.8 mg/day)
Study: 32791720
Drug: Ear molding
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ear molding treatment for 2 weeks within 3 days after birth
Study: 36512912
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg (Arm 1)
Study: 36512912
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg plus tremelimumab 75 mg every 4 weeks (Arm 2)
Study: 32619648
Drug: Omission of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omission of week 5 chemotherapy
Study: 32619648
Drug: Dose reductions/delays
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose reductions/delays of week 5 chemotherapy
Study: 32619648
Drug: Receiving the
Normalized name: THE-630
DrugBank: THE-630 (DB16750)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receiving the target radiotherapy dose in >42 days
Study: 36441436
Drug: Naltrexone (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (50 mg daily)
Study: 32072743
Drug: HIV combination
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV combination prevention package including universal testing and treatment
Study: 35368954
Drug: Magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Magnesium sulfate (single drug group)
Study: 33227569
Drug: Pyridoxine treatment
Normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pyridoxine treatment
Study: 33004239
Drug: DAR-901 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAR-901 vaccine (1 mg, three intradermal injections at 0, 2, and 4 months)
Study: 33004239
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline placebo (three intradermal injections at 0, 2, and 4 months)
Study: 33004239
Drug: DAR-901 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAR-901 vaccine (1 mg)
Study: 35750727
Drug: Traditional implant
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional implant guide (traditional impression)
Study: 33759846
Drug: Online interactive
Normalized name: Menin-mll interaction inhibitor ko 539
DrugBank: Ziftomenib (DB17171)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online interactive case-based training on evidence-based practice (EBP) related to medication use in autism
Study: 35060851
Drug: Prednisolone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (15 mg/m2 for 6 days)
Study: 35285944
Drug: Oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral low-dose isotretinoin (0.2–0.4 mg/kg/d) combined with 30% salicylic acid chemical peeling
Study: 35285944
Drug: Oral low-dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral low-dose isotretinoin
Study: 32692788
Drug: Topical budesonide
Normalized name: budesonide Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical budesonide irrigations
Study: 32687588
Drug: Reduced-dose capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Reduced-dose capecitabine plus cetuximab as maintenance therapy
Study: 32687588
Drug: Fluorouracil-based chemotherapy
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluorouracil-based chemotherapy combined with cetuximab (induction therapy)
Study: 34008442
Drug: Insulin pen
Normalized name: INSULIN PEN (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pen
Study: 36348150
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (LEDT)
Study: 34579095
Drug: RES-500 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: RES-500 (500 mg RES/day)
Study: 34579095
Drug: RES-1000 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: RES-1000 (1000 mg RES/day)
Study: 34579095
Drug: RES (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: RES (both doses)
Study: 35048107
Drug: Polypill (aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan)
Study: 35048107
Drug: Polypill (aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill (aspirin, atorvastatin, hydrochlorothiazide, valsartan) in participants with pNASH
Study: 32340074
Drug: Biological with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological with Prevention (B + P)
Study: 32340074
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment arms (C + P, B + P, PA)
Study: 32963103
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (72 IU)
Study: 32963103
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (72 IU) with instructed mimicry
Study: 37137551
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with painful injection (hypertonic saline, 5.8%)
Study: 37137551
Drug: Exercise with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise with non-painful injection (isotonic saline, 0.9%)
Study: 37137551
Drug: Painful injection
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Painful injection (hypertonic saline, 5.8%)
Study: 37137551
Drug: Non-painful injection
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-painful injection (isotonic saline, 0.9%)
Study: 34417343
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous lidocaine infusion
Study: 34417343
Drug: Ultrasound-guided unilateral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided unilateral, single-injection TAP block
Study: 34648905
Drug: Coffee beverage
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee beverage A (400 mL/day containing 787 mg of chlorogenic acids)
Study: 34648905
Drug: Coffee beverage
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coffee beverage B (400 mL/day containing 407 mg of chlorogenic acids)
Study: 32619388
Drug: Non-biologics
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-biologics
Study: 33712253
Drug: 1 µg.kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg.kg-1 clonidine intravenously
Study: 34272849
Drug: lonapegsomatropin 0.24
Approvals — FDA: no, EMA: no, PMDA: no
Description: lonapegsomatropin 0.24 mg hGH/kg/week
Study: 34272849
Drug: daily somatropin
Normalized name: Somatropin
DrugBank: Somatotropin (DB00052)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: daily somatropin (equivalent weekly dose delivered daily)
Study: 32561603
Drug: MSCT monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCT monotherapy
Study: 32561603
Drug: MSCT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSCT plus recombinant human IFN-γ treatment
Study: 35242203
Drug: Dynamic monitoring
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic monitoring of lipid metabolism indexes and regulation of blood lipids on top of routine hypoglycemic treatment (Group B)
Study: 35242203
Drug: Routine hypoglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine hypoglycemic treatment (Control Group)
Study: 35242203
Drug: Combined detection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined detection of lipid metabolism indexes (TC, TG, HDL-C, LDL-C)
Study: 32003816
Drug: Telemedicine intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telemedicine intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Study: 32003816
Drug: In-person intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-person intervention (weekly for 4 weeks, every 2 weeks for 4 weeks, and monthly thereafter, provided relapse prevention therapy and buprenorphine)
Study: 35912650
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment (ET)
Study: 32041720
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept (Eylea) given via loading dose (three injections) followed by treat and extend protocol over 12 months
Study: 34014028
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg naltrexone
Study: 34014028
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg amitriptyline
Study: 34654525
Drug: Weekly participatory
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly participatory art-based activities at the Montreal Museum of Fine Arts over a 3-month period
Study: 33450079
Drug: ONO-7684 (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7684 (250 mg daily for 14 days)
Study: 33450079
Drug: ONO-7684 (1-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7684 (1-300 mg single doses)
Study: 33450079
Drug: ONO-7684 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7684 (single and multiple doses)
Study: 33450079
Drug: ONO-7684 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7684 (single doses)
Study: 33450079
Drug: ONO-7684 (multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ONO-7684 (multiple doses)
Study: 34846023
Drug: DBC treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DBC treatment with modern rehabilitation equipment
Study: 36006997
Drug: Routine physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine physical therapy (RPT)
Study: 33685871
Drug: App-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: App-based treatment (URinControl)
Study: 32041657
Drug: MTX 25
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX 25 mg (oral or subcutaneous) once weekly plus LEF 20 mg daily
Study: 32041657
Drug: Placebo instead
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo instead of LEF daily
Study: 32030734
Drug: Goal-directed fluid
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Goal-directed fluid therapy (n = 142)
Study: 32030734
Drug: Standard fluid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard fluid therapy (n = 141)
Study: 32890574
Drug: Ingestion group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion group (CMF) - at least 10 mL of cow's milk formula daily between 1 and 2 months of age
Study: 32890574
Drug: Avoidance group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avoidance group (no CMF) - avoid cow's milk formula and supplement with soy formula as needed
Study: 37798628
Drug: Custodiol cardioplegia
Normalized name: cardioplegia solutions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Custodiol cardioplegia (CC)
Study: 36484665
Drug: High-translucency zirconia
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-translucency zirconia with a partial buccal veneer (ZC-V)
Study: 32457995
Drug: Ceftazidime administered
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime administered by continuous infusion
Study: 32457995
Drug: Ceftazidime administered
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime administered by intermittent infusion
Study: 35394149
Drug: Intramyocardial administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramyocardial administration of autologous neonatal c-kit+ cardiac-derived progenitor cells (nCPCs)
Study: 35394149
Drug: Randomized, double-blinded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Randomized, double-blinded administration of nCPCs
Study: 34900170
Drug: Glucantime plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime plus SinaAmpholeish (topical nano-liposomal amphotericin B 0.4%)
Study: 34900170
Drug: Glucantime (intralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucantime (intralesional injections)
Study: 33761143
Drug: 1.91 g
Normalized name: CAMPHOR (SYNTHETIC) 1.91 g in 100 g / MENTHOL 2.54 g in 100 g / METHYL SALICYLATE 1.62 g in 100 g TRANSDERMAL PLASTER [She Xiang Zhuang Gu Gao]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.91 g of red clover extract (containing 8 mg formononetin and 1.8 mg biochanin A)
Study: 35995103
Drug: Very Low
Normalized name: Very low fat spread
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very Low Nicotine Content (VLNC) cigarettes (0.4 mg/g of tobacco)
Study: 35995103
Drug: Normal Nicotine
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Normal Nicotine Content (NNC) cigarettes (15.8 mg/g of tobacco)
Study: 35172043
Drug: New tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet, fasted (reference, dosed twice)
Study: 35172043
Drug: New tablet,
Approvals — FDA: no, EMA: no, PMDA: no
Description: New tablet, 30 minutes after a high-fat meal (test 1)
Study: 35172043
Drug: Old tablet,
Normalized name: Allergy/Cold Tablet, 12 mg-75 mg oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Old tablet, fasted (test 2)
Study: 32912974
Drug: Metacognitive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metacognitive therapy (MCT) plus usual care (UC)
Study: 33649520
Drug: rostafuroxin 50
Normalized name: Rostafuroxin
DrugBank: Rostafuroxin (DB12350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: rostafuroxin 50 μg
Study: 35074878
Drug: High-cash gift
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-cash gift group (monthly unconditional cash gift)
Study: 35074878
Drug: Low-cash gift
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-cash gift group (nominal monthly unconditional cash gift)
Study: 35931480
Drug: Probiotic treatment
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic treatment (PB) with 2 g of PBF1 added to colostrum and 1 g of PBF2 added to milk 3 times per week until weaning
Study: 34003963
Drug: All subjects
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All subjects (treatment agnostic)
Study: 35832128
Drug: Continuous care
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous care based on the combination of medical care and nursing (Observation Group)
Study: 34695679
Drug: Parent-administered early
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent-administered early intervention
Study: 35777616
Drug: Hybrid pegylated
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid pegylated liposomal doxorubicin (PLD) hydrochloride injection
Study: 32003645
Drug: Ubiquinol-10 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ubiquinol-10 (300 mg/day)
Study: 32988951
Drug: MyndMove neuromodulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MyndMove neuromodulation therapy
Study: 32156479
Drug: Other antihypertensive
Normalized name: Other antihypertensives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antihypertensive drugs (Control)
Study: 35881397
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care with normal saline infusion (control)
Study: 35241369
Drug: AC plus
Normalized name: Therevac Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: AC plus 0.5 µg of Vit D (Bon One 0.5 µg) orally once daily during the whole treatment course
Study: 34761610
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CCRT) after surgery
Study: 32649808
Drug: Sectional border
Normalized name: secobarbital sodium Oral Capsule [Seconal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sectional border molding technique using green stick compound (Z-group)
Study: 34786906
Drug: Focused extracorporeal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Focused extracorporeal shock wave therapy (f-ESWT) on myofascial points
Study: 34786906
Drug: Traditional focused
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional focused extracorporeal shock wave therapy (ESWT) on the medial calcaneal tubercle
Study: 33009565
Drug: Fluoride varnish
Normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoride varnish (1.5% ammonium fluoride) applied every sixth week during orthodontic treatment
Study: 33009565
Drug: Placebo varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo varnish (non-fluoride) applied every sixth week during orthodontic treatment
Study: 36264751
Drug: Prophylactic negative-pressure
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic negative-pressure wound therapy (pNPWT) for 7 days
Study: 36264751
Drug: Prophylactic negative-pressure
Normalized name: polylactic acid-polyglycolic acid copolymer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic negative-pressure wound therapy (pNPWT)
Study: 33825304
Drug: Dexmedetomidine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.5 µg/g, group D)
Study: 33825304
Drug: Midazolam (0.08
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.08 mg/kg, group M)
Study: 33454739
Drug: Opioid antagonist
Normalized name: OPIOID ANTAGONIST ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid antagonist
Study: 32661106
Drug: Euglycemia, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia, low insulin (EuLoI)
Study: 32661106
Drug: Hyperglycemia, low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperglycemia, low insulin (HyLoI)
Study: 32661106
Drug: Euglycemia, high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglycemia, high insulin (EuHiI)
Study: 34808255
Drug: Prophylactic gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic gabapentin (600 mg thrice daily)
Study: 32822633
Drug: Atogepant 10
Normalized name: atogepant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 10 mg once daily
Study: 32822633
Drug: Atogepant 30
Normalized name: atogepant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 30 mg once daily
Study: 38773375
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg once daily
Study: 32822633
Drug: Atogepant 30
Normalized name: atogepant 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 30 mg twice daily
Study: 32822633
Drug: Atogepant 60
Normalized name: atogepant 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atogepant 60 mg twice daily
Study: 36149220
Drug: Toothpaste with
Normalized name: SODIUM MONOFLUOROPHOSPHATE 1.1 g in 100 g DENTAL PASTE [Orbitol Fluoride Toothpaste with Baking Soda]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Toothpaste with sodium monofluorophosphate formulation